company background image
LMAT logo

LeMaitre Vascular NasdaqGM:LMAT Stock Report

Last Price

US$96.93

Market Cap

US$2.2b

7D

0.04%

1Y

65.1%

Updated

02 Feb, 2025

Data

Company Financials +

LeMaitre Vascular, Inc.

NasdaqGM:LMAT Stock Report

Market Cap: US$2.2b

LMAT Stock Overview

Develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. More details

LMAT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 12.18% per year

Earnings grew by 51.5% over the past year

Risk Analysis

LMAT passed our risk checks.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
Analyst Price Target
Consensus Narrative from 9 Analysts

Expanding Into APAC And EMEA Will Boost Operational Efficiency

Key Takeaways Expansion in international markets and new offices aims to drive revenue growth and improve operational efficiency. Strategic pricing and regulatory advancements are likely to enhance margins and foster future revenue increases.
View narrative
US$98.78
FV
1.9% undervalued intrinsic discount
9.34%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
3 days ago author updated this narrative

My Notes

Capture your thoughts, links and company narrative

LeMaitre Vascular, Inc. Competitors

CONMED

NYSE:CNMD

US$2.2b

LivaNova

NasdaqGS:LIVN

US$2.7b

InMode

NasdaqGS:INMD

US$1.5b

Integer Holdings

NYSE:ITGR

US$4.8b

Price History & Performance

Summary of share price highs, lows and changes for LeMaitre Vascular
Historical stock prices
Current Share PriceUS$96.93
52 Week HighUS$109.58
52 Week LowUS$57.60
Beta0.96
1 Month Change5.66%
3 Month Change0.60%
1 Year Change65.13%
3 Year Change130.51%
5 Year Change230.93%
Change since IPO1,463.39%

Recent News & Updates

We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease

Jan 22
We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease

LeMaitre Vascular: Losing Steam

Jan 15

A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Jan 09
A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward

Dec 22
LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings

Nov 24
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings

Recent updates

We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease

Jan 22
We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease

LeMaitre Vascular: Losing Steam

Jan 15

A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Jan 09
A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward

Dec 22
LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings

Nov 24
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings

LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story

Nov 03

LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 02
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?

Oct 08
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?

Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)

Sep 17
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings

Sep 04
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings

If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity

Aug 22
If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity

LeMaitre Vascular: A Small Cap With Best-In-Industry Growth

Jul 23

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?

Jul 12
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?

Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Jun 18
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing

Jun 05
Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear

May 02
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear

Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?

Apr 04
Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Feb 29
Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Jan 19
What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

Oct 27
Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Oct 11
Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

Aug 30
Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Jul 06
The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

May 20
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Mar 12
Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Oct 23
Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Shareholder Returns

LMATUS Medical EquipmentUS Market
7D0.04%-0.1%-0.9%
1Y65.1%13.7%22.6%

Return vs Industry: LMAT exceeded the US Medical Equipment industry which returned 13.7% over the past year.

Return vs Market: LMAT exceeded the US Market which returned 22.6% over the past year.

Price Volatility

Is LMAT's price volatile compared to industry and market?
LMAT volatility
LMAT Average Weekly Movement4.2%
Medical Equipment Industry Average Movement8.8%
Market Average Movement6.4%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: LMAT has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: LMAT's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1983622George LeMaitrewww.lemaitre.com

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries.

LeMaitre Vascular, Inc. Fundamentals Summary

How do LeMaitre Vascular's earnings and revenue compare to its market cap?
LMAT fundamental statistics
Market capUS$2.18b
Earnings (TTM)US$41.32m
Revenue (TTM)US$213.03m

52.7x

P/E Ratio

10.2x

P/S Ratio

Is LMAT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LMAT income statement (TTM)
RevenueUS$213.03m
Cost of RevenueUS$67.45m
Gross ProfitUS$145.58m
Other ExpensesUS$104.26m
EarningsUS$41.32m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)1.84
Gross Margin68.34%
Net Profit Margin19.40%
Debt/Equity Ratio0%

How did LMAT perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

34%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 02:24
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LeMaitre Vascular, Inc. is covered by 22 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Raymond MyersBenchmark Company
Jan WaldBenchmark Company